Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analysts give Silence Therapeutics an average recommendation of Moderate Buy across seven brokerages (2 sell, 4 buy, 1 strong buy) with a consensus 12‑month price target of $34.50.
• Fundamentals remain weak: SLN trades near $5.94 with a market cap of about $280.6M and a 52‑week range of $1.97–$7.91, while reporting negative EPS, minimal revenue, and an extremely negative net margin this quarter.
• Institutional ownership is very high at ~98.73%, with recent buying from firms such as Millennium Management, which increased its stake to 659,592 shares (~$4.01M).

Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven brokerages that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $34.50.

Several research analysts have issued reports on SLN shares. HC Wainwright reaffirmed a "buy" rating and set a $75.00 price objective on shares of Silence Therapeutics in a report on Friday, March 13th. William Blair reiterated an "outperform" rating on shares of Silence Therapeutics in a research report on Monday, March 2nd. Jefferies Financial Group raised Silence Therapeutics to a "strong-buy" rating in a report on Wednesday, March 18th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Silence Therapeutics in a research report on Thursday, January 22nd.

Silence Therapeutics Stock Performance

Shares of NASDAQ SLN opened at $5.94 on Friday. The business has a fifty day moving average of $5.43 and a two-hundred day moving average of $5.88. Silence Therapeutics has a 52-week low of $1.97 and a 52-week high of $7.91. The stock has a market cap of $280.55 million, a PE ratio of -3.18 and a beta of 1.33.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last issued its quarterly earnings data on Friday, March 6th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.07. Silence Therapeutics had a negative net margin of 15,851.88% and a negative return on equity of 101.71%. The firm had revenue of $0.03 million for the quarter, compared to analysts' expectations of $2.19 million. Analysts predict that Silence Therapeutics will post -1.77 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of SLN. Seven Fleet Capital Management LP acquired a new position in shares of Silence Therapeutics in the 4th quarter valued at $897,000. XTX Topco Ltd acquired a new position in Silence Therapeutics in the 4th quarter worth $71,000. Quadrature Capital Ltd bought a new position in Silence Therapeutics during the 4th quarter worth about $331,000. Opaleye Management Inc. acquired a new stake in shares of Silence Therapeutics in the 4th quarter valued at about $480,000. Finally, Millennium Management LLC lifted its holdings in shares of Silence Therapeutics by 121.0% in the fourth quarter. Millennium Management LLC now owns 659,592 shares of the company's stock valued at $4,010,000 after purchasing an additional 361,080 shares in the last quarter. Institutional investors and hedge funds own 98.73% of the company's stock.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence's technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company's lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.